Table 2.
The lifetime risk of CVD up to age 95 adjusted for the competing risk of death for men and women at age 35, 45 and 55 according to individual fasting blood glucose variability (CV)
| FBG variability category (CV, %) | Total | Men | Women | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No. of CVD case/total | Lifetime risk% (95%CI) | P-value | No. of CVD case/total | Lifetime risk% (95%CI) | P-value | No. of CVD case/total | Lifetime risk% (95%CI) | P-value | |
| 35 years | |||||||||
| Low (< 6.19) | 528/15339 | 26.3 (23.0, 29.5) | Ref | 455/11262 | 28.0 (24.5, 31.4) | Ref | 73/4077 | 17.8 (11.3, 24.2) | Ref |
| Intermediate (6.19–10.86) | 603/15340 | 28.3 (25.5, 31.1) | 0.357 | 547/11676 | 30.8 (27.9, 33.8) | 0.214 | 56/3664 | 13.8 (9.6, 18.1) | 0.316 |
| High (> 10.86) | 758/15339 | 32.5 (28.9, 36.1) | 0.013 | 688/12124 | 34.7 (30.9, 38.5) | 0.010 | 70/3215 | 18.1 (10.6, 25.7) | 0.942 |
| 45 years | |||||||||
| Low (< 6.26) | 502/12713 | 26.0 (22.8, 29.3) | Ref | 430/9519 | 27.5 (24.1, 31.0) | Ref | 72/3194 | 17.9 (11.5, 24.2) | Ref |
| Intermediate (6.26%-11.03%) | 584/12720 | 27.7 (25.0, 30.5) | 0.443 | 528/9755 | 30.1 (27.2, 33.1) | 0.269 | 56/2965 | 14.1 (9.9, 18.4) | 0.335 |
| High (> 11.03%) | 704/12716 | 32.1 (28.3, 35.9) | 0.018 | 638/10042 | 34.4 (30.5, 38.4) | 0.011 | 66/2674 | 18.0 (9.4, 26.5) | 0.990 |
| 55 years | |||||||||
| Low (< 6.57%) | 345/7041 | 24.6 (21.3, 28.0) | Ref | 294/5533 | 25.9 (22.3, 29.5) | Ref | 51/1508 | 16.4 (10.2, 22.5) | Ref |
| Intermediate (6.57–11.40) | 408/7042 | 25.6 (22.8, 28.4) | 0.655 | 364/5505 | 27.6 (24.5, 30.7) | 0.468 | 44/1537 | 13.5 (9.1, 18.0) | 0.464 |
| High (> 11.40) | 468/7041 | 30.4 (26.3, 34.5) | 0.032 | 423/5532 | 32.5 (28.2, 36.8) | 0.020 | 45/1509 | 16.8 (7.8, 25.8) | 0.937 |
CVD Cardiovascular diseases, FBG Fasting blood glucose, CV Coefficient of variation
Lifetime risk estimates represent the percentage of cohort participants who would experience a total CVD event from the index age to the end of follow-up if the last participant in the cohort were to die at the last age of follow-up (95 years)